文献速递角膜与眼表疾病

角膜内皮功能障碍:认识演变与治疗选择

Corneal endothelial dysfunction: Evolving understanding and treatment options.
PubMed 文献 · Prog Retin Eye Res · 2020-09-22

角膜内皮层精密调控角膜水化以维持透明,内皮功能障碍或损伤可致角膜水肿和视力损害。选择性角膜内皮移植术安全有效但供体短缺限制可及性,目前多项临床试验探索去除中央病变内皮后自行恢复、培养人角膜内皮细胞扩增、诱导多能干细胞、基因治疗等替代方案。

要点

  • 选择性角膜内皮移植术可实现快速视力康复,但全球供体角膜短缺限制其可及性。
  • 临床试验正在评估健康周边内皮患者去除功能障碍中央内皮后的自行恢复潜力。
  • 培养人角膜内皮细胞、诱导多能干细胞、基因治疗等临床前或临床研究正在探索中。

核心结论

  • 角膜内皮功能障碍可致角膜水肿和视力损害,选择性内皮移植术安全有效但供体短缺,多种替代疗法正在研发中以扩大治疗可及性并实现个体化治疗。

主要发现

  • 选择性角膜内皮移植术的技术改进已最小化并发症,并可通过多种调整用于解剖结构复杂的患眼。
  • 临床试验正在评估健康周边内皮患者去除功能障碍中央内皮后的自行恢复潜力。
  • 培养人角膜内皮细胞的多种应用正在临床试验中,旨在从单个供体角膜扩增细胞供可能数百名患者使用。
  • 诱导多能干细胞、内皮干细胞再生、基因治疗、反义寡核苷酸及多种生物/药理方法的临床前研究正在进行。

临床怎么用

  • 对符合条件的角膜内皮功能障碍患者,选择性角膜内皮移植术可实现快速视力康复且并发症已最小化。
  • 在供体角膜短缺地区,可关注去除中央病变内皮后自行恢复及培养内皮细胞等替代疗法的临床试验进展。

局限性

  • 全球许多地区供体角膜短缺限制选择性内皮移植术的可及性。
  • 培养内皮细胞、诱导多能干细胞、基因治疗等替代方案尚在临床试验或临床前研究阶段。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The cornea is exquisitely designed to protect the eye while transmitting and focusing incoming light. Precise control of corneal hydration by the endothelial cell layer that lines the inner surface of the cornea is required for optimal transparency, and endothelial dysfunction or damage can result in corneal edema and visual impairment. Advances in corneal transplantation now allow selective replacement of dysfunctional corneal endothelium, providing rapid visual rehabilitation. A series of technique improvements have minimized complications and various adaptations allow use even in eyes with complicated anatomy. While selective endothelial keratoplasty sets a very high standard for safety and efficacy, a shortage of donor corneas in many parts of the world restricts access, prompting a search for alternatives. Clinical trials are underway to evaluate the potential for self-recovery after removal of dysfunctional central endothelium in patients with healthy peripheral endothelium. Various approaches to using cultured human corneal endothelial cells are also in clinical trials; these aim to multiply cells from a single donor cornea for use in potentially hundreds of patients. Pre-clinical studies are underway with induced pluripotent stem cells, endothelial stem cell regeneration, gene therapy, anti-sense oligonucleotides, and various biologic/pharmacologic approaches designed to treat, prevent, or retard corneal endothelial dysfunction. The availability of more therapeutic options will hopefully expand access around the world while also allowing treatment to be more precisely tailored to each individual patient.

来源:Prog Retin Eye Res,查看原文。版权归原作者所有。

引用

  1. Price MO, Mehta JS, Jurkunas UV, et al. Corneal endothelial dysfunction: Evolving understanding and treatment options. Prog Retin Eye Res. 2020. PMID: 32977001. doi:10.1016/j.preteyeres.2020.100904

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。